Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Diovan
Synonyms :
Class :
Angiotensin receptor blockers
Brand Name :
Diovan
Synonyms :
Class :
Angiotensin receptor blockers
Dosage Forms & Strengths
Tablet
40mg
80mg
160mg
320mg
Patients who don't have volume depletion
80-160 mg orally daily
maximum dose is 320 mg orally daily
If further antihypertensive impact is necessary, the dose may be increased to a maximum of 320 mg daily or a diuretic may be added
The majority of the antihypertensive impact is felt within the first two weeks, and the maximum decrease is often reached after four weeks
Higher impact than dosage increases of more than 80 mg is the addition of a diuretic
Congestive Heart Failure (CHF)
40 mg orally 2 times daily
Increase up tp 80-160 mg
Consider lowering the dosage of any concurrent diuretics
Maximum daily dosage of 320 mg was given in split doses during clinical studies
May begin as soon as 12 hours after MI
20 mg orally 2 times a day
may increase to 40 mg orally 2 times a day after 7 days
with successive titrations to the goal maintenance dosage of 160 mg twice a day as tolerated
Dosage Forms & Strengths
Tablet
40mg
80mg
160mg
320mg
Age: > 1 year
1 mg/kg orally daily
Modify dosage according on blood pressure response
Consider a larger initial dosage of 2 mg/kg in select situations if a greater drop in blood pressure is required
may enhance the concentration of serum in valsartan
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
It may enhance the toxicity effects when combined with moexipril
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increased adverse effect when combined with angiotensin-converting enzyme inhibitors
may increase the adverse/toxic effect of angiotensin ii receptor blockers
may increase the adverse/toxic effect of angiotensin ii receptor blockers
aliskiren: they may increase the hyperkalemic effect of Angiotensin II Receptor antagonists
may increase the adverse effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
may enhance the serum concentration of angiotensin ii receptor blockers
may enhance the serum concentration of angiotensin ii receptor blockers
It may enhance the toxicity effects when combined with moexipril by pharmacodynamic synergism
may have an increased risk of renal failure, hypertension, and hyperkalemia when combined with valsartan
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may increase the nephrotoxic effect of angiotensin ii receptor blockers
may increase the nephrotoxic effect of angiotensin ii receptor blockers
may increase the nephrotoxic effect of angiotensin ii receptor blockers
when metronidazole and valsartan are combined, their metabolism can be slowed down
may have an increasingly adverse effect when combined with NSAIDs
when combined with valsartan, the excretion of cholecystokinin may be decreased
it increases the effect of hyperkalemia of angiotensin II receptor blockers
it may increase the toxicity of each other
may enhance the effects of the other by pharmacodynamic synergism
may increase the orthostatic hypotensive effect of dapoxetine
may have an increased hyperkalemic effect when combined with angiotensin ii receptor blockers
polyethylene glycol and electrolytes
It may increase the nephrotoxic effect when combined with polyethylene Glycol-electrolyte Solution
nicorandil: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
they decrease the effect of hypertension of angiotensin II
they decrease the effect of hypertension of angiotensin II
they decrease the effect of hypertension of angiotensin II
they decrease the effect of hypertension of angiotensin II
they decrease the effect of hypertension of angiotensin II
the hyperkalemic activity of valsartan may be increased
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
Adverse drug reactions:
Frequency Defined
>10%
Hypertension, adult
Dry cough
Arthralgia (3%)
Fatigue (3%)
Hyperkalemia (2%)
Hypotension, postural (2%)
Dizziness (17%)
Hypotension (7%)
Dizziness, postural (2%)
1-10%
Increased serum creatinine ≥50% (3.9%)
Heart failure
>1%
Nausea
Headache
Renal impairment
Syncope
Upper abdominal pain
Vertigo
Blurred vision
Post MI H4
Neutropenia (1.9%)
Increased serum creatinine ≥50% (4.2%)
Hypotension NOS (1.4%)
<1%
Old MI
Increased blood creatinine (0.6%)
Cough (0.6%)
Rash NOS (0.2%
Pregnancy warnings:
AU TGA pregnancy category: D
US FDA pregnancy category: Not assigned. Lactation:
Excreted into human milk is Unknown
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: valsartan
Why do we use valsartan?
valsartan is an Angiotensin receptor blocker which is used to treat hypertension, heart attack, and myocardial infarction.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
